Phibro Animal Health earnings and guidance set the tone

Phibro Animal Health (PAHC) drew investor attention after issuing earnings guidance for the fiscal year ending June 30, 2027, alongside reporting fourth quarter and full year 2026 results.

The company now projects 2027 net sales of US$1.55b to US$1.60b and net income of US$122 million to US$132 million. Expected diluted EPS is US$2.98 to US$3.22. These figures follow 2026 sales of US$1,518.09 million and net income of US$99.72 million.

Phibro Animal Health's latest guidance and earnings came after a strong run in the stock, with a 90 day share price return of 17.95% and a three year total shareholder return above 200%, while the 1 year total shareholder return has slightly declined.

Compare Phibro Animal Health's momentum and guidance with a curated group of resilient stocks in our 82 resilient stocks with low risk scores that pair relatively lower risk profiles with solid fundamentals.

After a sharp move in Phibro Animal Health and a wide gap between its current price and published value estimates, the real puzzle is where fair value clusters within that range and how much of the recent optimism is already in the stock.

Most Popular Narrative: 16.1% Undervalued

On the latest close at $38.25, the most followed narrative tags Phibro Animal Health with a fair value of $45.60, using a detailed forecast of earnings, margins and valuation multiples to justify that gap.

The analysts have a consensus price target of $45.6 for Phibro Animal Health based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $58.0, and the most bearish reporting a price target of just $38.0.

Read the complete narrative. Read the complete narrative.

Want to see what supports a higher valuation for Phibro Animal Health? The story leans on measured revenue growth, rising margins and a future earnings multiple that still sits below sector benchmarks.

Result: Fair Value of $45.60 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Phibro Animal Health also carries risks, including tighter regulations on antimicrobials and pressure on future earnings assumptions if industry growth and margins fall short of analyst models.

Find out about the key risks to this Phibro Animal Health narrative.

Next Steps

Given the mix of optimism and concern around Phibro Animal Health, this is a moment to move quickly and check the underlying data yourself. To see the balance of potential upside and downside in one place, review the 4 key rewards and 1 important warning sign